Relugolix in the management of prostate cancer

ABSTRACT Introduction Relugolix is the first oral gonadotrophin-releasing hormone (GnRH) receptor antagonist. Based on the phase III HERO trial results, relugolix received Food and Drug Administration approval for adult patients with advanced prostate cancer (PCa). Areas covered We provide an overview of the preclinical and clinical development of relugolix and its role in the current treatment landscape of PCa. Expert opinion Relugolix leads to rapid inhibition of testicular production of testosterone and its rapid recovery upon discontinuation. In the HERO trial, relugolix was associated with a superior cardiovascular safety profile compared to GnRH agonists. These attributes make relugolix a promising therapy for patients with preexisting cardiovascular comorbidities, those pursuing intermittent androgen deprivation therapy, and those who desire rapid testosterone recovery during ‘off-treatment’ periods. In the HERO trial, very few patients received concomitant enzalutamide (n = 17, 2.7%) or docetaxel (n < 10, 1.3%). Safety of relugolix has not been established in combination with many androgen-receptor-axis targeted therapies (e.g. abiraterone, apalutamide), cabazitaxel, or lutetium Lu 177 vipivotide tetraxetan, which precludes its use in combination with these agents. In addition, being an oral drug, relugolix may also be associated with challenges of affordability, adherence, and compliance in this predominantly elderly population.

[1]  Shenglin Tang,et al.  An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma , 2022, Frontiers in Pharmacology.

[2]  N. Shore,et al.  Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer. , 2022, Future oncology.

[3]  C. Ng,et al.  Letter by Ng et al Regarding Article, "Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial". , 2022, Circulation.

[4]  T. Dorff,et al.  Real-world experience with relugolix. , 2022, Journal of Clinical Oncology.

[5]  D. George,et al.  Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix verus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study. , 2022, Journal of Clinical Oncology.

[6]  J. Aragon-Ching,et al.  Advances with androgen deprivation therapy for prostate cancer , 2022, Expert opinion on pharmacotherapy.

[7]  N. Fleshner,et al.  Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers , 2022, Cancers.

[8]  Jingjing Yu,et al.  Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations , 2021, Drug Metabolism and Disposition.

[9]  P. Noseworthy,et al.  Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment , 2021, JAMA network open.

[10]  Deepak L. Bhatt,et al.  Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer , 2021, Circulation.

[11]  D. Dearnaley,et al.  Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer. , 2021, Future oncology.

[12]  H. Maeng,et al.  Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability , 2021, Pharmaceutics.

[13]  A. Papatsoris,et al.  Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer , 2021, Expert opinion on pharmacotherapy.

[14]  M. Michel,et al.  A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020 , 2021, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  F. Saad,et al.  Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer , 2021, Therapeutic advances in medical oncology.

[16]  F. Saad,et al.  Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study. , 2021 .

[17]  M. Kirby,et al.  Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice , 2020, World Journal of Urology.

[18]  F. Saad,et al.  Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. , 2020, The New England journal of medicine.

[19]  J. Sylvester,et al.  The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. , 2020, European urology.

[20]  E. Schaeffer,et al.  Surgical Versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. , 2019, The Journal of urology.

[21]  H. Akaza,et al.  Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer , 2019, Cancer medicine.

[22]  A. Markham.  Relugolix: First Global Approval , 2019, Drugs.

[23]  M. Gizzi,et al.  Advancing therapies in metastatic castration-resistant prostate cancer , 2018, Expert opinion on pharmacotherapy.

[24]  A. Papatsoris,et al.  Therapeutic outcomes of the LHRH antagonists , 2017, Expert review of pharmacoeconomics & outcomes research.

[25]  R. Eckel,et al.  The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. , 2017, Urologic oncology.

[26]  A. Sciarra,et al.  A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer , 2016, Medicine.

[27]  H. Payne,et al.  The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK , 2016, World Journal of Urology.

[28]  L. Klotz,et al.  Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials , 2016, Therapeutic advances in urology.

[29]  F. Saad,et al.  Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts). , 2016 .

[30]  F. Saad,et al.  Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. , 2015, The Journal of clinical endocrinology and metabolism.

[31]  A. Fabiano,et al.  Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  M. Asada,et al.  Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. , 2014, European journal of pharmacology.

[33]  N. Vélez de Mendizábal,et al.  Pharmacokinetic/Pharmacodynamic Model of the Testosterone Effects of Triptorelin Administered in Sustained Release Formulations in Patients with Prostate Cancer , 2012, Journal of Pharmacology and Experimental Therapeutics.

[34]  E. Crawford,et al.  A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. , 2011, The Journal of urology.

[35]  T. Hitaka,et al.  Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. , 2011, Journal of medicinal chemistry.

[36]  L. Klotz,et al.  Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. , 2010, The Journal of urology.

[37]  M. Marberger,et al.  Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. , 2010, Clinical therapeutics.

[38]  D. Jocham,et al.  Degarelix for prostate cancer , 2009, Expert opinion on investigational drugs.

[39]  J. Morote,et al.  Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy , 2009, BJU international.

[40]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[41]  D. Steyn,et al.  Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer , 2009, Clinical drug investigation.

[42]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[43]  B. Persson,et al.  A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. , 2008, The Journal of urology.

[44]  B. Tombal,et al.  Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. , 2008, European urology.

[45]  K. Miller,et al.  Management of advanced prostate cancer: can we improve on androgen deprivation therapy? , 2008, BJU international.

[46]  A. Schally.  Luteinizing hormone‐releasing hormone analogues and hormone ablation for prostate cancer: state of the art , 2007, BJU international.

[47]  F. Debruyne,et al.  Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. , 2006, Future oncology.

[48]  J. Morote,et al.  Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer , 2006, Urologia Internationalis.

[49]  J. Rivier,et al.  Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. , 2005, Journal of medicinal chemistry.

[50]  D. Weckermann.  Reply to Ph. Weston, B.-E. Persson , 2005 .

[51]  P. Teillac,et al.  Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer , 2004, Expert opinion on pharmacotherapy.

[52]  G. Reddy.  Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer. , 2004, Clinical prostate cancer.

[53]  F. Debruyne.  Gonadotropin-releasing hormone antagonist in the management of prostate cancer. , 2004, Reviews in urology.

[54]  Masataka Harada,et al.  Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. , 2003, Journal of medicinal chemistry.

[55]  John Trachtenberg,et al.  A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. , 2002, The Journal of urology.

[56]  Jean E Rivier,et al.  Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. , 2002, The Journal of pharmacology and experimental therapeutics.

[57]  D. Gleason,et al.  A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. , 2001, Urology.

[58]  M. Menon,et al.  The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. , 2001, The Journal of urology.

[59]  J. Rivier,et al.  GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. , 2001, Journal of medicinal chemistry.

[60]  D. Jacqmin,et al.  Three-Month Sustained-Release Form of Triptorelin in Patients with Advanced Prostatic Adenocarcinoma: Results of an Open Pharmacodynamic and Pharmacokinetic Multicenter Study , 1998, Hormone Research in Paediatrics.